At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLYM CLIMB BIO INC
Market Closed 02-27 16:00:00 EST
7.15
-0.23
-3.12%
盘后7.10
-0.05-0.70%
19:02 EST
High7.59Low7.10Vol582.31K
Open7.20D1 Closing7.38Amplitude6.64%
Mkt Cap341.37MTradable Cap219.85MTotal Shares47.74M
T/O4.28MT/O Rate1.89%Tradable Shares30.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Climb Bio Director Thomas Stephen Basil Disposes of Common Shares
Reuters  ·  05:05
Climb Bio Director Thomas Stephen Basil Disposes of Common Shares
Climb Bio Director Thomas Stephen Basil Reports Disposal of Common Shares
Reuters  ·  02-18
Climb Bio Director Thomas Stephen Basil Reports Disposal of Common Shares
Piper Sandler Initiates Climb Bio at Overweight With $23 Price Target
MT Newswires Live  ·  02-13
Piper Sandler Initiates Climb Bio at Overweight With $23 Price Target
Climb Bio Initiated at Overweight by Piper Sandler
Dow Jones  ·  02-13
Climb Bio Initiated at Overweight by Piper Sandler
U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections
Reuters  ·  02-13
U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections
Climb Bio Inc. to Participate in Major Healthcare Investor Conferences
Reuters  ·  02-05
Climb Bio Inc. to Participate in Major Healthcare Investor Conferences
Ten new option listings and two option delistings on January 22nd
TIPRANKS  ·  01-22
Ten new option listings and two option delistings on January 22nd
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO)
TIPRANKS  ·  01-09
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO)
Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028
Reuters  ·  01-08
Climb Bio Inc. Outlines 2026 Strategy With Multiple Clinical Trial Readouts, Expanded Pipeline in Immune-Mediated Diseases, and Financial Guidance Extending Operations Into 2028
Climb Bio Inc. Expands Leadership Team and Board with Key Appointments
Reuters  ·  01-08
Climb Bio Inc. Expands Leadership Team and Board with Key Appointments
Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116
Reuters  ·  01-08
Climb Bio Reports Progress in Clinical Trials for Budoprutug and CLYM116
Climb Bio Inc: First Patients Dosed in Budoprutug Prismn Phase 2 Trial in Pmn, With Initial Data Expected Second Half 2026
THOMSON REUTERS  ·  01-08
Climb Bio Inc: First Patients Dosed in Budoprutug Prismn Phase 2 Trial in Pmn, With Initial Data Expected Second Half 2026
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
THOMSON REUTERS  ·  01-08
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
Climb Bio Inc - Cash Runway Expected Into 2028
THOMSON REUTERS  ·  01-08
Climb Bio Inc - Cash Runway Expected Into 2028
RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares
Reuters  ·  01-08
RA Capital Management Reports Acquisition of Climb Bio Inc. Common Shares
BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing
Reuters  ·  01-01
BRIEF-Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing
Climb Bio Inc - Files Complaint Against Alumis and ACELYRIN - SEC Filing
THOMSON REUTERS  ·  01-01
Climb Bio Inc - Files Complaint Against Alumis and ACELYRIN - SEC Filing
Climb Bio Inc - Complaint Seeks Declaratory Judgment That Co's Budoprutug Drug Candidate Is Not "Product" Under Apa
THOMSON REUTERS  ·  01-01
Climb Bio Inc - Complaint Seeks Declaratory Judgment That Co's Budoprutug Drug Candidate Is Not "Product" Under Apa
Climb Bio Inc - Does Not Owe a Milestone Payment Sought by Alumis in Connection With Its Development of Budoprutug
THOMSON REUTERS  ·  01-01
Climb Bio Inc - Does Not Owe a Milestone Payment Sought by Alumis in Connection With Its Development of Budoprutug
Climb Bio Inc - Complaint Relating to a Dispute Concerning an Asset Purchase Agreement, Dated as of January 11, 2024
THOMSON REUTERS  ·  01-01
Climb Bio Inc - Complaint Relating to a Dispute Concerning an Asset Purchase Agreement, Dated as of January 11, 2024

Introduction

Company Name.
CLIMB BIO INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Issue price:
--